Neurocrine biosciences reports first quarter 2023 financial results

Ingrezza® (valbenazine) first quarter net product sales of $410 million ingrezza® (valbenazine) 2023 net product sales guidance reiterated at $1.67 - $1.77 billion san diego , may 3, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the first quarter ended march 31, 2023 and provided an update on its 2023 financial guidance. "ingrezza's first quarter results highlight the steady progress we are making to help improve the lives of patients living with tardive dyskinesia, yet we still have a tremendous opportunity to help even more patients for many years to come," said kevin gorman, ph.d.
NBIX Ratings Summary
NBIX Quant Ranking